Stepan Company (SCL) Q4 2023 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2023 earnings summary
31 Oct, 2026Executive summary
FY2023 sales volume declined 11% amid broad end-market weakness and customer/channel destocking; Adjusted EBITDA fell to $180.0M from $301.5M.
Q4 volume rose 3% YoY, led by Polymers; reported net loss was $1.2M versus net income of $10.8M, and Adjusted EBITDA declined to $37.5M from $40.0M.
Cost controls and inventory reduction supported cash generation while strategic investments continued.
Financial highlights
FY net income was $40.2M versus $147.2M in 2022; Adjusted Net Income was $50.7M versus $153.5M.
FY net sales fell 16% to $2.326B; operating income was $58.6M versus $207.3M, and diluted EPS was $1.75 versus $6.38.
Q4 net sales fell 15% YoY to $532.1M; operating income was $0.2M versus $11.7M.
Q4 Adjusted Net Income was $7.5M, or $0.33 per diluted share, versus $13.5M, or $0.59; Adjusted EBITDA was $37.5M versus $40.0M.
FY cash from operations was $174.9M, up 9% YoY; inventory fell $137M from Dec. 31, 2022.
Outlook and guidance
2024 outlook calls for Adjusted EBITDA growth and positive free cash flow, supported by market recovery, strategic initiatives and cost reductions.
Volumes and margins are expected to improve with Rigid Polyols recovery, contracted Surfactant growth, lower raw material costs and Agricultural Chemicals recovery in H2; agricultural destocking may continue through H1.
Planned 2024 pre-tax cost savings of $50M are intended to offset inflation, Pasadena commissioning and Low 1,4 Dioxane operating costs, and higher incentive compensation.
2024 capex is forecast at $120–140M; the effective tax rate is forecast at 36–38%, with projected federal cash taxes of zero.
Latest events from Stepan Company
- Q3 adjusted EBITDA rose 18% on 7% organic volume growth; deleveraging remains a priority.SCL
Q3 2026 - Margin recovery accelerates with 45% EBITDA growth and strategic shift to higher-margin segments.SCL
17th Annual Midwest IDEAS Conference - Q2 2026 adjusted EBITDA rose 45% to $74.4M on strong segment growth and margin recovery.SCL
Q2 2026 - Net loss of $41.4M driven by restructuring, with adjusted EBITDA down 14% and sales up 2%.SCL
Q1 2026 - 2025 results highlight diversified growth, operational excellence, and a robust innovation pipeline.SCL
Investor presentation - Proxy covers director elections, pay practices, auditor ratification, and strong governance.SCL
Proxy filing - Adjusted EBITDA grew 6% in 2025; Project Catalyst targets $100M in savings, with H2 2026 recovery expected.SCL
Q4 2025 - Q3 net income up 88% to $23.6M, EBITDA up 11%, with strong Surfactants and cost savings.SCL
Q3 2024 - Adjusted EBITDA grew 4% in Q2 2024 despite lower net income and significant one-time expenses.SCL
Q2 2024